A prospective observational study of patients receiving Dupixent for Atopic Dermatitis. ENROLLMENT OPEN https://clinicaltrials.gov/ct2/show/NCT03992417
A phase 3 randomized, placebo-controlled, double-blinded study to evaluate Upadacitinib in adolescents and adult subjects with moderate to severe Atopic Dermatitis. ENROLLMENT CLOSED https://clinicaltrials.gov/ct2/show/NCT03607422
A multicenter, open-label, randomized study to assess the pharmacokinetics, safety, and efficacy of two doses of Bimekizumab in adolescent study participants with moderate to severe plaque psoriasis.
A Phase 3B, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to Secukinumab or Ixekizumab and are switched to Risankizumab.
For more information contact Katy Martz at 660-956-7078 or email [email protected].